Abstract
Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.
| Original language | English |
|---|---|
| Pages (from-to) | 136-142 |
| Number of pages | 7 |
| Journal | Tuberculosis |
| Volume | 108 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
Cite this
}
A multicentre verification study of the QuantiFERON®-TB Gold Plus assay. / Pieterman, E. D.; Liqui Lung, F. G.; Verbon, A.; Bax, H. I.; Ang, C. W.; Berkhout, J.; Blaauw, G.; Brandenburg, A.; van Burgel, N. D.; Claessen, A.; van Dijk, K.; Heron, M.; Hooghiemstra, M.; Leussenkamp-Hummelink, R.; van Lochem, E.; van Loo, I. H.M.; Mulder, B.; Ott, A.; Pontesilli, O.; Reuwer, A.; Rombouts, P.; Saegeman, V.; Scholing, M.; Vainio, S.; de Steenwinkel, J. E.M.
In: Tuberculosis, Vol. 108, 01.01.2018, p. 136-142.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - A multicentre verification study of the QuantiFERON®-TB Gold Plus assay
AU - Pieterman, E. D.
AU - Liqui Lung, F. G.
AU - Verbon, A.
AU - Bax, H. I.
AU - Ang, C. W.
AU - Berkhout, J.
AU - Blaauw, G.
AU - Brandenburg, A.
AU - van Burgel, N. D.
AU - Claessen, A.
AU - van Dijk, K.
AU - Heron, M.
AU - Hooghiemstra, M.
AU - Leussenkamp-Hummelink, R.
AU - van Lochem, E.
AU - van Loo, I. H.M.
AU - Mulder, B.
AU - Ott, A.
AU - Pontesilli, O.
AU - Reuwer, A.
AU - Rombouts, P.
AU - Saegeman, V.
AU - Scholing, M.
AU - Vainio, S.
AU - de Steenwinkel, J. E.M.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.
AB - Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.
KW - Interferon-gamma release assay
KW - Latent tuberculosis infection
KW - QuantiFERON-TB Gold In Tube
KW - QuantiFERON-TB Gold Plus
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85036573566&partnerID=8YFLogxK
U2 - 10.1016/j.tube.2017.11.014
DO - 10.1016/j.tube.2017.11.014
M3 - Article
VL - 108
SP - 136
EP - 142
JO - Tuberculosis
JF - Tuberculosis
SN - 1472-9792
ER -